Key result
CCTA-guided CABG showed 99% feasibility and 92% 30-day graft patency, while integrating polygenic risk scores with SCORE2 reclassified 9.55% of intermediate-risk individuals to high risk.
Answers are grounded in this paper and cite their sources.
For the podcast associated with this article, please visit https://academic.oup.com/eurheartj/pages/Podcasts. This Focus Issue on ischaemic heart disease and arrhythmias contains a State of the Art Review entitled ‘Atherosclerosis evaluation and cardiovascular risk estimation using coronary computed tomography angiography’ from Nick Nurmohamed from the Vrije Universiteit Amsterdam in the Netherlands and colleagues.1 The authors point out that clinical risk scores based on traditional risk factors of atherosclerosis correlate imprecisely to an individual’s complex pathophysiological predisposition to atherosclerosis and provide limited accuracy for predicting major adverse cardiovascular events (MACE).2–7 Over the past two decades, computed tomography scanners and techniques for coronary computed tomography angiography (CCTA) analysis have substantially improved, enabling more precise atherosclerotic plaque quantification and characterization. The accuracy of CCTA for quantifying stenosis and atherosclerosis has been validated in numerous multicentre studies and has shown consistent incremental prognostic value for MACE over the clinical risk spectrum in different populations. Serial CCTA studies have advanced our understanding of vascular biology and atherosclerotic disease progression. The direct disease visualization of CCTA has the potential to be used synergistically with indirect markers of risk to significantly improve prevention of MACE, pending large-scale randomized evaluation (Figure 1). Of note, the most successful preventive care paradigms have relied upon advanced imaging for direct visualization including mammograms, colonoscopies, and lung CT for early identification and treatment of breast, colon and lung cancer, respectively. Thus, it is conceivable that emulation of these approaches for coronary artery disease (CAD) prevention over sole use of indirect risk factors may hold the potential to improve patient outcomes. This review evaluates (i) the current use of coronary CCTA in clinical practice, (ii) its role in quantifying and characterizing CAD as the primary determinant for future MACE in symptomatic patients, (iii) its role in asymptomatic individuals or populations, and (iv) future directions for clinical trials investigating the role of CCTA in a personalized approach to prevent atherosclerotic cardiovascular disease. Coronary computed tomography angiography (CCTA) can change the population risk-based approach to a personalized care approach and provides important clinical utility. Coronary computed tomography angiography allows for precise atherosclerotic plaque quantification and characterization, and CCTA studies have advanced our understanding of vascular biology that holds potential to change our population risk-based approach to a personalized care approach. Coronary computed tomography angiography also provides clinical utility for assessment of drug efficacy and as a gatekeeper to cardiac catheterization lab. AUC, area under the curve; CAD, coronary artery disease; CCTA, coronary computed tomography angiography; HDL-C, high-density lipoprotein cholesterol1 In a Viewpoint article entitled ‘Calmodulin, sudden death, and the Folbigg case: genes in court’, Peter Schwartz from the Istituto Auxologico Italiano in Milan, Italy and colleagues point out that justice and science do not meet often; when they do, the rendezvous is usually in court, as happened in the Folbigg case.8 Between 1989 and 1999, in New South Wales (NSW), Australia, four infants were discovered by the mother, Kathleen Folbigg (KF), having died suddenly during their sleep. In May 2003, a jury found the mother guilty of murdering three of her children and of manslaughter and sentenced her to 40 years in jail. She became known as ‘Australia’s worst female serial killer’, a monster. In 2019, two geneticists, Carola Vinuesa and Todor Arsov, sequenced DNA from the mother and the dead infants and found that three of the four girls had a G114R variant in the CALM2 gene encoding calmodulin, a ubiquitous and essential calcium-binding protein critically involved in countless intracellular signalling processes. Then, on 13 December 2023, Folbigg’s convictions were quashed by the top Criminal Court in NSW. She was acquitted on all counts, ‘on the basis of the new scientific evidence’. This evidence is new data from the ICalmR published by the authors of this Viewpoint in this Journal.9 In a Fast Track Clinical Research article entitled ‘Coronary bypass surgery guided by computed tomography in a low-risk population’, Patrick Serruys from the University of Galway in Ireland and colleagues indicate that in their study coronary artery bypass grafting (CABG) procedures were planned based on CCTA without knowledge of invasive coronary angiography (ICA). The CABG strategy was recommended by a central core laboratory assessing the anatomy and functionality of coronary circulation.10 The primary feasibility endpoint was the percentage of operations performed without access to the ICA. The primary safety endpoint was graft patency on 30-day follow-up CCTA. Secondary endpoints included topographical adequacy of grafting, major adverse cardiac and cerebrovascular (MACCE) and major bleeding events at 30 days. The study enrolled 114 patients with a mean anatomical SYNTAX score and Society of Thoracic Surgery score of 44 and 0.81, respectively. Unblinding ICA was required in one case, yielding a feasibility of 99%. The concordance and agreement in revascularization planning between the ICA- and CCTA-Heart Teams was 83% and between the CCTA-Heart Team and actual treatment was 84%. The 30-day follow-up CCTA in 102 patients (92%) showed an anastomosis patency rate of 92%, whereas MACCE was 7.2% and major bleeding 2.7%. Serruys et al. conclude that CABG guided by CCTA is feasible and has an acceptable safety profile in a selected population of complex CAD. The contribution is accompanied by an Editorial by Lamia Harik and Mario Gaudino from Weill Cornell Medicine in New York, USA.11 The authors note that it is critically important to highlight that Serruys’ results should only be seen as hypothesis-generating, and the CABG CCTA hypothesis must now be tested in adequately powered randomized comparative trials. Despite the limitations described above, Serruys et al. should be commended on an innovative proof-of-concept study that may lead to a larger research effort that can potentially change CABG practice and improve the outcomes of patients with coronary artery disease. Ischaemic stroke (IS) is a major complication of atrial fibrillation (AF).12,13 Female sex has been linked with IS in AF, but no prior study has examined temporal trends in the IS risk associated with female sex. In a Clinical Research article entitled ‘Ischaemic stroke in women with atrial fibrillation: temporal trends and clinical implications’, Konsta Teppo from the University of Turku in Finland and colleagues point out that the registry-linkage Finnish AntiCoagulation in Atrial Fibrillation (FinACAF) study included all patients with AF in Finland from 2007 to 2018.14 IS rates and rate ratios were computed. Overall, about 230 000 patients with new-onset AF were identified (50% women; mean age 73 years). The crude IS incidence was higher in women than in men across the entire study period (21 vs. 15 events per 1000 patient-years, P < .001), and the incidence decreased both in men and women. In 2007–08, female sex was independently associated with a 20–30% higher IS rate in the adjusted analyses, but this association attenuated and became statistically non-significant by the end of the observation period (Figure 2). Similar trends were observed when time with and without oral anticoagulant (OAC) treatment was analysed, as well as when only time without OAC use was considered. The decrease in IS rate was driven by patients with high IS risk, whereas in patients with low or moderate IS risk, female sex was not associated with a higher IS rate. Temporal trends in the association between female sex and ischaemic stroke among patients with atrial fibrillation in Finland from 2007 to 201814 The authors conclude that the association between female sex and IS rate has decreased and become non-significant over the course of the study period from 2007 to 2018, suggesting that female sex could be omitted as a factor when estimating expected IS rates and the need for OAC therapy in patients with AF. This manuscript is accompanied by an Editorial by David Brieger and Ben Freedman from the Concord Repatriation General Hospital in Sydney, NSW, Australia.15 The authors note that at the present time we have no option but to persevere with existing scores, of which CHA2DS2VASc has been the most widely studied and adopted, but they support the authors in their suggestion that female sex should be omitted from this score. Thus, Brieger and Friedman hope that this study encourages others to look to their own data sets and replicate these analyses. Wider adoption of this practice would of course be anticipated if parity in contemporary risk of stroke and stroke rate between males and females with AF is demonstrated in other populations. Mitral valve prolapse (MVP) is a frequent cause of mitral insufficiency.16–20 Arrhythmic mitral valve prolapse (AMVP) is linked to life-threatening ventricular arrhythmias (VA), and young women are considered at high risk. In a Clinical Research article entitled ‘Mitral valve prolapse: arrhythmic risk during pregnancy and postpartum’, Eivind Westrum Aabel from Oslo University Hospital in Norway aimed to describe features of women with high-risk AMVP who developed malignant VA during the perinatal period, and to assess if pregnancy and the postpartum period were associated with a higher risk of malignant VA.21 This retrospective international multicentre case series included high-risk women with AMVP who experienced malignant VA and at least one pregnancy. Malignant VA included ventricular fibrillation, sustained ventricular tachycardia or appropriate shock from an implantable cardioverter defibrillator. The authors compared the incidence of malignant VA in non-pregnant periods and the perinatal period; the latter defined as occurring during pregnancy and within 6 months after delivery. The authors included 18 women with AMVP from 11 centres. During 7.5 years of follow-up, 37 malignant VA occurred, of which 18 were pregnancy-related occurring in 13 (72%) unique patients. Pregnancy and 6 months after delivery showed increased incidence rate of malignant VA compared to the non-pregnancy period (univariate incidence rate ratio 2.66). Aabel et al. conclude that the perinatal period could impose increased risk of malignant VA in women with high-risk AMVP. The data may provide general guidance for pre-conception counselling and for nuanced shared decision-making between patients and clinicians. The contribution is accompanied by an Editorial by Katja Zeppenfeld and Marta de Riva from Leiden University Medical Centre in the Netherlands.22 The authors highlight that the prevalence of MVP is 2–3%. The crux of the matter lies in identifying the minority of patients at increased risk for sudden cardiac death (SCD) within the larger population of subjects with MVP: how to pinpoint the proverbial needle in the haystack? All-cause cardiac maternal mortality is ≈0.0014%; thus, it is clear that SCD related to MVP during the perinatal period is very rare. However, women with malignant arrhythmogenic forms of MVP, such as those with an arrhythmic syncope or a prior cardiac arrest, may be perhaps more likely to suffer a malignant arrhythmia during pregnancy. Identifying these rare patients remains a significant challenge. No doubt, for this task, we need to join forces, as beautifully demonstrated by these investigators, but we should take care to avoid undue emphasis of this rare potential complication, which could have marked effects on many young women with MVP, including creating undue anxiety, until we have better data. It is not clear how a polygenic risk score (PRS) can be best combined with guideline-recommended tools for cardiovascular disease (CVD) risk prediction, e.g. SCORE2. In a Clinical Research article entitled ‘Integration of a polygenic score into guideline-recommended prediction of cardiovascular disease’, Ling Li from the Technische Universität München in Germany and colleagues calculated a PRS for CAD in participants of UK Biobank (n = 432 981). Within each tenth of the PRS distribution, the odds ratios (ORs)—referred to as PRS factor—for CVD (i.e. CAD or stroke) were compared between the entire population and subgroups representing the spectrum of clinical risk.23 Replication was performed in the combined Framingham/Atherosclerosis Risk in Communities populations (n = 10 757). The clinical suitability of a multiplicative model ‘SCORE2 × PRS-factor’ was tested by risk reclassification. In subgroups with highly different clinical risks, CVD ORs were stable within each PRS tenth. SCORE2 and PRS showed no significant interactive effects on CVD risk, which qualified them as multiplicative factors. In UK Biobank, the multiplicative model moved 9.55% of the intermediate-risk to the high-risk group, increasing the individuals in this category by 57%. Incident CVD occurred in 8.1% of individuals reclassified by the PRS factor from intermediate to high risk, which was about two-fold those remaining at intermediate risk (4.1%). Likewise, the PRS factor shifted 8.3% of individuals from moderate to high risk in Framingham/ARIC. The authors conclude that this study demonstrates that absolute CVD risk (determined by a clinical risk score) and relative genetic risk (determined by a PRS) provide independent information. The two components may form a simple multiplicative model improving precision of guideline-recommended tools in predicting incident CVD. The manuscript is accompanied by an Editorial by Mette Christoffersen, Stefan Stender and Anne Tybjærg-Hansen from Copenhagen University Hospital—Rigshospitalet in Denmark.23 The authors conclude that taken together, this innovative, very well-conducted and clinically relevant study by Li et al. has addressed some of the challenges preventing the clinical use of PRSs and brought us one step closer to implementation in daily clinical practice. Other obstacles remain, especially regarding the application, interpretation, limitations and communication of the PRS results to the treating clinician as well as to the patient. The issue also includes a Rapid Communications article entitled ‘Electronic nudges increase influenza vaccination utilization after myocardial infarction: the nationwide NUDGE-FLU implementation trial’ by Ankeet Bhatt from Stanford University Division of Cardiovascular Medicine in Palo Alto, CA (USA) and colleagues.24 The authors note that influenza infection is associated with accelerated atherogenesis and enhanced acute myocardial infarction (AMI) risk. Influenza vaccination in patients with recent AMI reduces the risk of MACE; routine vaccination now carries a Class IA recommendation following AMI in the most recent European Society of Cardiology guidelines. Strategies to improve vaccination rates in this high-risk cohort are needed. NUDGE-FLU was conducted during the 2022–23 influenza season as a nationwide, pragmatic randomized implementation trial. The design and results have been published previously. NUDGE-FLU included older Danish citizens eligible for free-of-charge influenza vaccination. Participants were randomized, clustered at the household, in a 9:1:1:1:1:1:1:1:1:1 ratio to usual care or nine different intervention arms utilizing variations of behaviourally designed electronic letters, including a cardiovascular gain frame letter highlighting the cardiovascular benefits of vaccination. In this secondary analysis of NUDGE-FLU, the authors evaluated the effects of electronic letters vs. usual care on vaccination rates among those with AMI. In the overall NUDGE-FLU trial, letters highlighting the potential cardiovascular benefits of vaccination modestly improved influenza vaccination rates. In this study the authors observed consistent benefits in vaccine uptake for the cardiovascular gain frame letter vs. usual care among patients with a history of AMI compared to those without. Type of presenting AMI did not modify the effectiveness of the cardiovascular gain frame letter vs. usual care. Among patients with AMI, the vaccination uptake benefits of the cardiovascular gain frame letter were consistent regardless of recency of AMI. The authors conclude that in this post-hoc analysis of a nationwide implementation trial, an electronic letter emphasizing the potential cardiovascular benefits of vaccination boosts uptake of influenza vaccination regardless of history of AMI. The editors hope that this issue of the European Heart Journal will find the interest of its readers. Dr. Crea reports speaker fees from Abbott, Amgen, Astra Zeneca, BMS, Chiesi, Daiichi Sankyo, Menarini outside the submitted work. With thanks to Amelia Meier-Batschelet, Johanna Huggler, and Martin Meyer for help with compilation of this article.
No takes yet. Share an insight, caveat, or question.
Filippo Crea (2024) conducted an editorial in Ischaemic heart disease and arrhythmias. Coronary computed tomography angiography, polygenic risk scores, and electronic nudges was evaluated. CCTA-guided CABG showed 99% feasibility and 92% 30-day graft patency, while integrating polygenic risk scores with SCORE2 reclassified 9.55% of intermediate-risk individuals to high risk.
Synapse has enriched 10 related papers. Consider them for comparative context: